Full-Life Technologies celebrated the groundbreaking of its new GMP manufacturing facility in Jambroux, Belgium in December 2023. Credit: Full-Life Technologies.
The new facility will strengthen the company’s radiopharmaceutical manufacturing capabilities. Credit: Fulllife Technologies.
The new facility will be developed on a site of 17,000 square meters. Credit: Fulllife Technologies.
Fulllife Technologies, a fully integrated radiotherapy company, held a groundbreaking ceremony in December 2023 for its new Good Manufacturing Practice (GMP) radiopharmaceutical manufacturing facility in Jambroux, Wallonia, Belgium.
The new facility will expand the company’s current radiopharmaceutical manufacturing capabilities and ensure timely delivery of radiotherapy drugs to patients around the world.
position
The company signed a land sales contract of 17,000 square meters² (182,986 feet²) Land for construction of facility in May 2023.
Jambroux is a major hub for pharmaceutical production and is located within Europe’s biotechnology innovation corridor. The new facility was chosen because of its geographical location, state-of-the-art infrastructure, specialized talent pool and efficient transportation network.
The Wallonia government plays an important role in creating a favorable environment for the radiopharmaceutical industry.
Learn more about Full-Life Technologies’ GMP manufacturing facility
Full Life Technologies’ GMP manufacturing facility spans 4,000 square meters² .
The facility will serve as the company’s production hub for manufacturing end-to-end solutions and a wide range of radiopharmaceuticals that meet GMP standards for major markets.
Featuring a sustainable design, the facility will be equipped with automation technology and a digital quality assurance system.
Learn more about Full-Life Technologies’ radiopharmaceutical products
Full-Life Technologies is focused on manufacturing radionuclide drug conjugates (RDCs) and radiotherapy drugs for various cancer indications under various programs.
The company’s strong candidates are 225Ac-FL-020 is a novel prostate-specific membrane antigen being developed for the treatment of metastatic castration-resistant prostate cancer. This drug candidate is designed to deliver the highly potent actinium-225 alpha emitter isotope. The drug is currently undergoing Phase I clinical trials, which are expected to begin in early 2024 in Europe and the United States.
Full-Life Technologies is also developing the somatostatin receptor 2 (SSTR2) and cholecystokinin B receptor (CCKBR/CCK2R) receptors for the treatment of small cell lung cancer (SCLC), neuroendocrine tumors, and medullary thyroid cancer. We are evaluating actinium-225 as a heavy-target drug.
Neurotensin receptor type 1 has been developed to target squamous cell carcinoma of the head and neck and gastrointestinal cancers, and guanylyl cyclase C receptor has been developed to target colorectal, gastric, and pancreatic cancers.
The company’s UniRDC™ is a unique discovery platform that helps streamline and accelerate the discovery of RDC drug candidates within 18 months. Covers a wide range of modalities including small molecules, cyclic peptides, and nanobodies.
The platform is based on a unique set of synthetic chemistry and protein engineering tool kits, including Clear-X.™ Linker technology and Res-X™ Modification methods that enable the development of RDC candidates with optimal biodistribution profiles.
financing
Full Life Technologies closed on $63.3 million in financing in January 2024, including $47.3 million in Series B equity financing and a $16 million line of credit.
The company plans to use the $16 million financing facility to construct a new facility and develop its product pipeline.
Full-Life Technologies Marketing Commentary
Full Life Technologies aims to establish a value chain consisting of radiopharmaceutical research, development, production, and commercialization to deliver lifesaving radiotherapy drugs to cancer patients and people with unmet medical needs. ing.
The company was founded in August 2021 and operates in Belgium, Germany and China. In November 2022, the company acquired radiopharmaceutical development company Focus-X Therapeutics to expand its radiopharmaceutical pipeline focused on peptides.
Full-Life Technologies is also focused on establishing strategic collaborations and partnerships that leverage its technology and explore licensing opportunities that complement its drug development pipeline. We collaborate with key supply chain partners to ensure timely delivery of products to customers around the world.